Experts wrap up their discussion of emerging chronic kidney disease tests and treatments with key takeaways for providers and patients.
Dhiren Patel, PharmD: Thank you, Dr Busch, for joining us on this episode of Patient CareÒ. We learned a lot today. Could [you] just quickly summarize for our audience the value of the KidneyIntelX test.
Robert Busch, MD: Just like how medicine evolved in other fields, we have many different drug classes that can benefit the kidneys, but are you going to give all the drugs to every patient who has a GFR [glomerular filtration rate] that’s a little bit low, below 90 and urine microalbumin a little high? Or are you going to have a bioprognostic test that will segment the risk in the individual patient to say, “You’re going to go on to bad kidney disease. I’m going to do the works with you,” vs someone else where the test doesn’t look bad, so you might be controlling their blood pressure, but you don’t have to throw the book at them and give them every drug that we have available. So this would define who you’re going to do the works with, with the drugs that we have, RAS, SGLT2 [sodium-glucose cotransporter 2], finerenone, and maybe GLP1 [glucagon-like peptide 1], vs [in whom] you’re going to just treat the diabetes aggressively, give them the RAS, keep their blood pressure down, so it would help you know who to be very aggressive with vas who to be less aggressive [with]. And these are new markers and an artificial intelligence summation of these markers to give you a point score that tells you a low, medium, or high risk [so you can] act accordingly.
Dhiren Patel, PharmD: Thank you so much.
Transcript was AI-generated and edited for clarity.